Novo Nordisk, the pharmaceutical giant, has revealed preliminary study results showing that its pill performed better than blockbuster shots. Study participants who took the medication, called amyretin, lost 13 percent of their body weight over 12 weeks, exceeding the amount of weight lost from its obesity jab Wegovy, which was 6 percent over the same time period. The groundbreaking results, which have not yet been stood up by strict scientific scrutiny, propelled the company to the ranking of 12th most valuable company with a valuation of $566 billion, surpassing that of and Visa.
Load More
Load More